共 50 条
Two large steps forward, one small step back
被引:0
|作者:
Marcus-Alexander Wörns
Peter R. Galle
机构:
[1] University Medical Centre of the Johannes Gutenberg-University,Department of Internal Medicine I and the Cirrhosis Centre Mainz (CCM)
来源:
关键词:
D O I:
暂无
中图分类号:
学科分类号:
摘要:
In 2017, the FDA approved regorafenib and nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib treatment, opening the door for an effective systemic second-line therapy in advanced disease. By contrast, the addition of sorafenib to transarterial chemoembolization with drug-eluting beads did not improve progression-free survival in the intermediate disease stage.
引用
收藏
页码:74 / 76
页数:2
相关论文